Summary
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K on July 30, 2026, primarily to announce its financial results for the second quarter ended June 30, 2026. While the filing itself does not contain the detailed financial figures, it directs investors to an accompanying press release (Exhibit 99.1) for the full earnings announcement. Investors should refer to this press release for critical information regarding the company's performance, revenue, profitability, and any forward-looking guidance.
Key Highlights
- 1Alnylam Pharmaceuticals reported its Q2 2026 financial results on July 30, 2026.
- 2The detailed financial results and operational updates are available in the press release furnished as Exhibit 99.1.
- 3Investors are advised to review the press release for comprehensive financial performance data.
- 4The filing serves as notification of the earnings release and directs stakeholders to the relevant document.
- 5Information provided under Item 2.02 is furnished and not deemed 'filed' under Section 18 of the Exchange Act.
Frequently Asked Questions
Alnylam's Q2 2026 financial results are detailed in the press release furnished as Exhibit 99.1 to the 8-K filing dated July 30, 2026. You should refer to this press release for specific financial and operational information.
The filing date of July 30, 2026, indicates when Alnylam Pharmaceuticals officially announced its financial results for the second quarter ended June 30, 2026, making this information available to the public.
The information furnished under Item 2.02 of this Form 8-K, including the press release, is generally considered 'furnished' and not 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it is not subject to the same liabilities as formally filed documents, though it is still important for investors to review for disclosed information.